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Abstract
Purpose Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospec-
tive study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC).
Methods 117 patients undergoing MC were compared to 112 patients, eligible for this treatment, but undergoing best sup-
portive care (BSC) after sorafenib discontinuation for toxicity or HCC progression. The two groups were compared for 
demographic and clinical features. A multivariate regression analysis was conducted to detect independent prognostic factors. 
To balance confounding factors between the two groups, a propensity score model based on independent prognosticators 
(performance status, neoplastic thrombosis, causes of sorafenib discontinuation and pre-sorafenib treatment) was performed.
Results Patients undergoing MC showed better performance status, lower tumor burden, lower prevalence of portal vein 
thrombosis, and better cancer stage. Median (95% CI) post-sorafenib survival (PSS) was longer in MC than in BSC patients 
[9.5 (7.5–11.6) vs 5.0 (4.2–5.7) months (p < 0.001)]. Neoplastic thrombosis, cause of sorafenib discontinuation, pre-sorafenib 
treatment and MC were independent prognosticators. The benefit of capecitabine was confirmed in patients after matching 
with propensity score [PSS: 9.9 (6.8–12.9) vs. 5.8 (4.8–6.8) months, (p = 0.001)]. MC lowered the mortality risk by about 
40%. MC achieved better results in patients who stopped sorafenib for adverse events than in those who progressed during 
it [PSS: 17.3 (10.5–24.1) vs. 7.8 (5.2–10.1) months, (p = 0.035)]. Treatment toxicity was low and easily manageable with 
dose modulation.
Conclusions MC may be an efficient and safe second-line systemic therapy for HCC patients who discontinued sorafenib 
for toxicity or tumor progression.
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Introduction
The oral multi-tyrosine kinase inhibitor sorafenib currently 
represents the only evidence-based treatment for advanced 
hepatocellular carcinoma (HCC) in patients with preserved 
liver function. However, phase 3 trials and field practice 
surveys have shown that 80–91% of treated patients expe-
rience adverse events (AEs), leading to dose reductions 
in about half cases and a treatment discontinuation in 
28–40% of them (Llovet et al. 2008; Iavarone et al. 2011; 
Lencioni et al. 2014). Moreover, sorafenib fails to control 
cancer progression in about 30–40% of patients (Llovet 
et al. 2008; Iavarone et al. 2011). According to data avail-
able in the literature, a percentage ranging from 40 to 56% 
of patients who fails sorafenib is potentially amenable to 
second-line clinical trials (Llovet et al. 2013; Reig et al. 
2013; Shao et al. 2014). So far, several different antican-
cer agents, such as brivanib, ramucirumab and everolimus 
have failed to improve survival as second-line treatments 
in phase 3 randomized controlled trials (RCTs) (Llovet 
et al. 2013; Finn et al. 2012; Zhu et al. 2014, 2015). The 
reasons of these failures may be either an inadequate 
stratification of patients or the intrinsic toxicity of some 
of these drugs that cause severe AEs, the occurrence of 
which is facilitated by the co-presence of cirrhosis (Llo-
vet et al. 2015). More recently, this dismal scenario has 
been partially modified by regorafenib, a potent multiki-
nase inhibitor, that succeeded in improving the survival of 
patients tolerant to sorafenib but with cancer progression, 
compared with placebo (Bruix et al. 2017). Indeed, even 
this new cornerstone of systemic therapy for HCC does 
not accomplish the need of patients who do not tolerate 
sorafenib.
Capecitabine, a prodrug of 5-f luorouracil (5-FU) 
metabolized to the active drug preferentially in liver and 
tumor tissue by thymidine phosphorylase (Walko and 
Lindley 2005), has been tested as first- and second-line 
treatment for HCC by some studies, using either the con-
ventional or metronomic approach (Patt et al. 2004; Lee 
et al. 2009; Farrag 2012; He et al. 2013; Abdel-Rahman 
et al. 2013; Brandi et al. 2013; Granito et al. 2015; Murer 
et al. 2016; Casadei Gardini et al. 2017). The obtained 
results are sparse and rather conflicting, and only one of 
these studies compared capecitabine with best supportive 
care (BSC) in the setting of second-line therapy (Casa-
dei Gardini et al. 2017). However, all the aforementioned 
investigations proved that capecitabine is well tolerated 
and, in particular, when the metronomic regimen (Kerbel 
and Kamen 2004; Cramarossa et al. 2014; Pasquier et al. 
2010) is utilized. This approach, recently used in oncol-
ogy, does not deliver high drug dose per unit time, nor 
is a cyclic maximum-tolerated dose regimen followed by 
prolonged drug-free breaks. It relies, instead, on continu-
ous administration of low drug doses, which reduce the 
gastrointestinal and bone marrow toxicity of chemotherapy 
(Kerbel and Kamen 2004). This is an important feature 
for the treatment of fragile patients, such as cirrhotic sub-
jects. The potential efficacy of metronomic chemotherapy 
depends on several mechanisms: (a) inhibition of tumoral 
angiogenesis due to a curbed production of growth factors 
by tumor micro-environmental cells; (b) reduction of the 
therapeutic resistance of the tumor; (c) activation of the 
adaptive and innate immune response through a reduction 
of immune-suppressive populations of regulatory T cells, 
an influence on dendritic and cytotoxic cells, and a recruit-
ment and activation of innate immune cells (Pasquier et al. 
2010; Kareva et al. 2015).
The effects of metronomic capecitabine (MC) in patients 
with advanced HCC was first tested by Farrag, who 
described a modest anti-tumor efficacy and a low toxicity 
of this treatment (Farrag 2012). Three pioneering studies 
have shown that MC is active and well tolerated in both 
treatment-naïve and sorafenib-experienced patients (Brandi 
et al. 2013; Granito et al. 2015; Casadei Gardini et al. 2017). 
However, none of them provided information about the 
potential influence of the cause of sorafenib discontinua-
tion (toxicity or failure to control cancer) on MC efficacy.
This multicentric study compares MC to BSC in HCC 
patients who discontinued sorafenib and explores whether 
causes of sorafenib withdrawal can affect outcomes of 
patients undergoing this therapy.
Materials and methods
We retrospectively analyzed the records of 335 HCC patients 
who were treated with sorafenib from January 1st 2009 to 
July 31st 2015 and discontinued treatment for cancer pro-
gression or intolerance (severe AEs) in the six centers: S. 
Orsola-Malpighi hospital, Bologna, University hospital of 
Pisa, Pisa, Careggi hospital, Florence, Department of Medi-
cal Oncology, Istituto Scientifico Romagnolo per lo Studio e 
Cura dei Tumori (IRST) IRCCS, Meldola, Ospedale per gli 
Infermi, Faenza, and Cardarelli hospital, Naples.
Sorafenib intolerance was defined as the occurrence of 
intolerable toxicity despite supportive therapy and/or dose 
reduction (to a minimum of 400 mg/day), or after 1 week of 
sorafenib withdrawal, or recurring after its restart. AEs were 
graded according to the National Cancer Institute, Common 
Terminology Criteria for Adverse Events classification, ver-
sion 4 (Common Terminology Criteria for Adverse Events 
2009). Radiological tumor progression was defined accord-
ing to modified RECIST criteria (Lencioni and Llovet 2010).
We excluded 67 (20.0%) patients belonging to Child-
Pugh (C–P) class C, or Barcelona Clinical Liver Cancer 
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(BCLC) stage D or Eastern Cooperative Oncology Group-
performance status (PS) > 2 from the study. Among the 268 
selected patients, 117 were treated with MC (cases), while 
151 received BSC (controls), according to the policy of each 
center (Fig. 1). In particular, Bologna hospital started shift-
ing patients from sorafenib to MC in case of tumor progres-
sion or unacceptable drug-related toxicity since 2009, while 
Meldola, Faenza, Firenze and Pisa hospitals adopted this 
strategy in 2011. Conversely, Naples hospital never utilized 
this practice, and shifted patients to BSC.
The eligibility criteria for MC treatment were: Eastern 
Cooperative Oncology Group (ECOG) PS ≤ 2, C–P score ≤ 8, 
bilirubin ≤ 3 mg/dL, PS ≤ 2, platelet count ≥ 50,000/mmc, 
hemoglobin level > 9 g/dL, white blood cell count > 1500/
mmc, transaminases < 5 × the upper normal level, creati-
nine ≤ 1.5 mg/dL, no ascites or ascites controlled by diuret-
ics, encephalopathy ≤ 1, and no history of coronary disease 
or heart failure. The same criteria were utilized to select the 
control subjects among BSC-treated patients. As a result, 
the population enrolled in the study included 117 MC cases 
and 112 BSC controls.
Capecitabine was administered orally, at the dose of 
500 mg bid. At discretion of the referral treatment provider, 
this dosage could be increased up to 500 mg tid if the drug 
was well tolerated and the first radiological control showed 
signs of tumor progression. MC was continued until the 
occurrence of radiological and symptomatic (ECOG PS ≥ 3, 
2 and/or ≥ 2 unit increase of C–P score) progression of HCC 
or for unacceptable toxicity. Drug-related AEs were man-
aged with supportive therapy, dose reduction or treatment 
suspension.
Diagnosis of cirrhosis was based on the presence of an 
irregular liver profile at ultrasound, ultrasonographic/endo-
scopic signs of portal hypertension and clinical and/or labo-
ratory features.
The liver disease was attributed to:
• hepatitis C virus (HCV), if patients showed serum anti-
HCV antibody;
• hepatitis B virus (HBV), if patients were HBV surface 
antigen carriers (± hepatitis delta virus);
• alcohol, if the daily ethanol intake was > 60 g for women 
and > 80 g for men, for > 10 years, in the absence of any 
other cause of liver injury;
• non-alcoholic fatty liver disease (NAFLD)/non-alcoholic 
steatohepatitis, according to the American Association 
for the study of the liver practice guidelines;
• multiple causes, for any combination between viral infec-
tions, alcohol abuse and NAFLD;
• others, including hemochromatosis, Wilson disease, 
alpha-1 antitrypsin deficiency, primary biliary cholan-
gitis and sclerosing cholangitis.
HCC histology was available in 57 out of 117 (48.7%) 
cases and 54 out of 112 (48.2%) controls. In non-biopsied 
patients, HCC diagnosis was established according to Euro-
pean Association For The Study Of The Liver guidelines 
(Bruix et al. 2001; European Association For The Study Of 
The Liver 2012).
HCC was staged at the time of enrolment by multiphase-
computed tomography or magnetic resonance imaging 
according to the BCLC staging system (Bruix et al. 2005). 
Fig. 1  CONSORT diagram of 
the study
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Additional investigations were performed when clinically 
appropriate.
Both MC and BSC patients underwent laboratory and 
clinical follow-up monthly. Imaging procedures were 
repeated every 2–3 months in MC patients. Instead, in BSC 
controls, imaging techniques were performed only when 
considered clinically necessary and outside the intention of 
checking tumor progression.
Tumor response (TR) to MC was evaluated by modified 
Response Evaluation Criteria In Solid Tumours (Lencioni 
and Llovet 2010), as MC also has anti-angiogenic effects.
All patients provided signed informed consent to the 
study. Patients receiving MC signed a further consent form 
for the administration of the second-line therapy. The study 
was approved by the Institutional board of the participating 
groups.
Statistical analysis
The primary end points were post-sorafenib survival (PSS) 
and overall survival from the beginning of sorafenib admin-
istration (OS), while secondary end points were MC safety 
and the best TR to MC. Continuous data were expressed 
as mean ± standard deviation (SD) or median and intervals, 
while discrete variables as absolute value and relative fre-
quency. Mann–Whitney U test was used to compare con-
tinuous data; χ2 Pearson’s test and Fisher’s test to compare 
discrete data. OS was measured from the day of sorafenib 
discontinuation to death, with values censored at 2015 July 
31st (end of the study) or at the last evaluation. Survival 
was analyzed by a Kaplan–Meier test, and differences were 
assessed by the log-rank test. Variables associated with sur-
vival (p < 0.10) at univariate analysis were included in the 
multivariate regression Cox model.
A propensity score model was developed to control 
results for baseline variable imbalances between treat-
ment groups. A multivariate logistic regression analysis 
was applied to calculate the propensity score. This model 
provided a 1:1 matching without replacement between 
MC and BSC patients, using the exact matching method 
(D’Agostino 1998). Survival analysis was repeated in the 
matched population. Statistical significance was met with 
2-tailed p value < 0.05. All statistical analyses were per-
formed with SPSS v23.0 (Apache Software Foundation, 
Chicago, Illinois).
Results
The main characteristics of the study population are reported 
in Table 1. Male sex accounted for about 80% of cases in 
both groups, whereas MC patients were slightly younger 
than BSC patients. There were no significant differences in 
etiology of liver disease, hepatic function [C–P class and 
Model for End Stage Liver Disease (MELD)] and meta-
bolic comorbidities. Instead, the two groups differed for the 
following features: MC patients showed a more frequently 
preserved PS (PS 0: 62.9 vs 49.1%, respectively, p = 0.007), 
smaller HCCs (4.7 vs 6.4 cm, p < 0.001), a lower prevalence 
of neoplastic thrombosis (23.1 vs 35.7%, p = 0.036) than 
BSC patients. Therefore, the distribution of BCLC stages 
was more favorable in MC than in BSC patients (p = 0.001). 
One-hundred and three (88%) MC patients and 65 (58.0%) 
BSC patients had undergone previous locoregional treatment 
of HCC (p < 0.001).
To minimize the confounding effect of the uneven distri-
bution of baseline characteristics, a propensity score match-
ing was performed. MC and BSC patients were matched 
for the independent prognosticators (at Cox models) which 
were: ECOG-PS, neoplastic thrombosis, causes of sorafenib 
discontinuation and pre-sorafenib treatments. The match-
ing allowed us to select 66 pairs of patients (1:1 case–con-
trol matching) homogeneous for all baseline characteris-
tics except the nodule size which was larger in BSC group 
(Table 2).
Median length of sorafenib treatment was 3.4 months 
(25th–75th : 1.9–8.2) in MC group and 3.6  months 
(25th–75th : 2.5–4.1) in BSC group (p = 0.609). MC was 
started after a median of 23 days (25th–75th : 11–44) from 
sorafenib discontinuation. The dosage of capecitabine was 
increased from 500 mg bid to 500 mg bid in 11 patients. 
Median length of MC treatment was 3.6 months (25th–75th: 
2.5–7.2). A dose reduction was necessary in six (5.1%) 
patients because of AEs. No patients required permanent 
drug withdrawal for this reason.
Radiological response and survival
Radiological evaluation was available in 95 (81.2%) MC 
patients and was missing in 22 patients due to an early 
worsening of health conditions preventing the radiological 
control or death occurrence. The best TR was: complete 
response in 1 (1.0%) patient who also showed a dramatic 
drop of alpha-fetoprotein (from 1909 to 2.6 ng/mL); partial 
response in 3 (3.2%); stable disease in 34 (35.8%) patients; 
disease progression in 57 (60.0%).
Median PSS was 9.5 months (95% CI 7.5–11.6) in MC 
patients and 5.0 months (95% CI 4.2–5.7) in BSC patients 
(p < 0.001) (Fig. 2a). After propensity score matching, the 
figures of PSS remained fairly similar to those of the origi-
nal treatment groups, with MC confirming its superiority 
over BSC [9.9 months (6.8–12.9) vs. 5.8 months (4.8–6.8), 
p = 0.001] (Fig. 2c).
Even OS (time from the start date of sorafenib therapy 
to death or last visit date) was significantly longer in MC 
than in BSC patients [16.7 (14.2–19.3) vs. 10.7 (8.4–13.1) 
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Table 1  Baseline characteristics 
of enrolled patients
Continuous variables are expressed as mean ± standard deviation (SD)
BMI body mass index; HCV hepatitis C virus; HBV hepatitis B virus; NAFLD non-alcoholic fatty liver dis-
ease; MELD model of end-stage liver disease; ECOG-PS eastern cooperative oncology group-performance 
status; CLIP, Cancer of the Liver Italian Program; BCLC Barcelona Clinic Liver Cancer; INR International 
Normalized Ratio; Hb hemoglobin; PLT platelet; GPT glutamic pyruvic transaminase; GOT glutamic 
oxaloacetic transaminase; AFP alpha-fetoprotein
Baseline characteristics Capecitabine group BSC group p values
Patients, n (%) 117 (51.1) 112 (48.9)
Age, years 68.0 ± 9.9 70.4 ± 10.7 0.016
Male, n (%) 92 (78.6) 88 (78.6) 1.000
Etiology (n 221), n (%)
 HCV 71 (64.0) 69 (62.7) 0.213
 HBV 15 (13.5) 10 (9.1)
 Alcohol 7 (6.3) 17 (15.5)
 NAFLD/cryptogenic 10 (9.0) 8 (7.3)
 Multiaetiology 8 (7.2) 5 (4.5)
 Others 0 (0) 1 (0.9)
Child–Pugh class (n 142) n (%) 0.858
 A 91 (77.8) 86 (76.8)
 B 26 (22.2) 26 (23.2)
MELD score 9.1 ± 2.6 9.4 ± 2.3 0.080
Hypertension, n (%) 43 (36.8) 51 (45.5) 0.177
Diabetes, n (%) 29 (24.8) 36 (32.1) 0.256
Ascites (n 142), n (%) 32 (27.6) 42 (38.9) 0.088
ECOG-PS (n 142) n (%) 0.007
 0 73 (62.9) 54 (49.1)
 1 40 (34.5) 45 (40.9)
 2 3 (2.6) 11 (10.0)
Portal vein thrombosis (n 143), n (%) 34 (29.3) 41 (36.9) 0.217
 Portal branch 20 (60.6) 30 (73.2)
 Segmental 7 (21.2) 6 (14.6)
 Both 6 (18.2) 5 (12.2)
Neoplastic thromobosis, n (%) 27 (23.1) 40 (35.7) 0.036
Metastasis (n 227), n (%) 74 (63.2) 84 (76.4) 0.043
Max. nodule size (mm) 47.3 ± 25.8 64.2 ± 34.1 < 0.001
Tumor spread (n 221), n (%) 0.869
 Unilobar 22 (20.0) 24 (21.6)
 Bilobar 88 (80.0) 87 (78.4)
BCLC, n (%) 0.001
 B 14 (12.0) 1 (0.9)
 C 103 (88.0) 111 (99.1)
Pre-sorafenib treatment, n (%) 103 (88.0) 65 (58.0) < 0.001
Sorafenib treatment duration, median (range) 3.4 months (1.9–8.2) 3.6 months (2.5–4.1) 0.609
Causes of sorafenib discontinuation (n 226), n (%) 0.139
 Progression 85 (72.6) 68 (62.4)
 Adverse events 31 (26.5) 37 (33.9)
 Liver failure 1 (0.9) 4 (3.7)
Clinical Biochemistry
 INR 1.2 ± 0.2 1.2 ± 0.1 0.291
 Bilirubin (mg/dL) 1.1 ± 0.6 1.2 ± 0.6 0.063
 Albumin (g/dL) 3.6 ± 0.5 3.5 ± 0.5 0.154
 Creatinine (mg/dL) 0.9 ± 0.3 0.9 ± 0.3 0.701
 Hb (g/dL) 12.2 ± 2.4 12.1 ± 2.2 0.385
 PLT (×  103/mmc) 166.2 ± 102.6 153.8 ± 83.5 0.801
 AFP (ng/mL) 5326 ± 15,410 4,442.2 ± 10,225 0.873
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Table 2  Baseline characteristics 
of patients after matching with 
the propensity score analysis 
for independent prognostic 
factors (ECOG-PS, neoplastic 
thrombosis, causes of sorafenib 
discontinuation and pre-
sorafenib treatments)
Continuous variables are expressed as mean ± standard deviation (SD) if not otherwise specified
BMI body mass index; HCV hepatitis C virus; HBV hepatitis B virus; NAFLD non-alcoholic fatty liver dis-
ease; MELD model of end-stage liver disease; ECOG-PS eastern cooperative oncology group-performance 
status; CLIP Cancer of the Liver Italian Program; BCLC Barcelona Clinic Liver Cancer; INR International 
Normalized Ratio; Hb hemoglobin; PLT platelet; GPT glutamic pyruvic transaminase, GOT glutamic 
oxaloacetic transaminase; AFP alpha-fetoprotein
Baseline characteristics Capecitabine group BSC group p values
Patients, n (%) 66 (56.4) 66 (58.9)
Age (years) 68.7 ± 9.3 69.3 ± 10.7 0.466
Male, n (%) 54 (81.8) 48 (72.7) 0.213
Etiology, n (%) 0.671
 HCV 40 (64.5) 44 (67.7)
 HBV 10 (16.1) 6 (9.2)
 Alcohol 3 (4.8) 6 (9.2)
 NAFLD/cryptogenic 5 (8.1) 6 (9.2)
 Multiaetiology 4 (6.5) 3 (4.6)
Child–Pugh class, n (%) 0.145
 A 47 (71.2) 55 (83.3)
 B 19 (28.8) 11 (16.7)
MELD score 8.9 ± 2.4 9.2 ± 2.3 0.395
Hypertension, n (%) 25 (37.9) 28 (42.4) 0.594
Diabetes, n (%) 18 (27.3) 23 (34.8) 0.347
Ascites, n (%) 24 (36.4) 23 (35.9) 0.960
ECOG-PS, n (%) 1.000
 0 40 (60.6) 40 (60.6)
 1 26 (39.4) 26 (39.4)
 2 0 (0.0) 0 (0.0)
Portal vein thrombosis, n (%) 22 (33.3) 17 (25.8) 0.516
 Portal branch 15 (68.2) 13 (76.5)
 Segmental 3 (13.6) 3 (17.6)
 Both 4 (18.2) 1 (5.9)
Neoplastic thromobosis, n (%) 19 (28.8) 19 (28.8) 1.000
Metastasis, n (%) 45 (68.2) 54 (81.8) 0.107
Max. nodule size (mm) 43.8 ± 27.8 59.9 ± 31.2 0.001
Tumor spread, n (%) 0. 806
 Unilobar 11 (18.3) 11 (16.7)
 Bilobar 49 (81.7) 55 (83.3)
BCLC, n (%) 0.115
 B 6 (9.1) 1 (1.5)
 C 60 (90.9) 65 (98.5)
Pre-sorafenib treatment, n (%) 52 (78.8) 52 (78.8) 1.000
Sorafenib treatment duration, median (25th–75th) 3.7 months (1.8–8.7) 3.8 months (1.9–8.5) 0.998
Causes of sorafenib discontinuation, n (%) 1.000
 Progression 51 (77.3) 51 (77.3)
 Adverse events 15 (22.7) 15 (22.7)
 Liver failure 0 (0.0) 0 (0.0)
 Other 0 (0.0) 0 (0.0)
Clinical Biochemistry
 INR 1.2 ± 0.2 1.1 ± 0.1 0.626
 Bilirubin (mg/dL) 1.1 ± 0.5 1.2 ± 0.6 0.436
 Albumin (g/dL) 3.5 ± 0.5 3.5 ± 0.5 0.865
 Creatinine (mg/dL) 0.8 ± 0.2 0.9 ± 0.3 0.757
 Hb (g/dL) 12.6 ± 1.6 11.8 ± 2.3 0.028
 PLT (×  103/mmc) 154.4 ± 91.7 146.7 ± 80.9 0.942
 AFP (ng/mL) 6153.8 ± 18,081.8 4394.7 ± 9476.5 0.834
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months; (p = 0.002)] (Fig. 2b). This difference was con-
firmed after propensity score matching [17.5 (14.2–20.8) 
vs. 12.0 (7.6–16.3) months; (p = 0.034)] (Fig. 2d).
At univariate analysis, ECOG-PS, C–P class, ascites, 
nodule size, neoplastic thrombosis, BCLC stage, reasons 
for sorafenib discontinuation, pre-sorafenib treatment, rea-
son for sorafenib discontinuation and MC therapy were 
associated with PSS (Table 3). To test all these variables 
in a multivariate model without incurring the bias of 
multicollinearity, three models were constructed: Model 
1 included MC therapy, C–P class,, BCLC stage, pre-
sorafenib treatment and reason for sorafenib discontinu-
ation; Model 2 comprises MC therapy, ECOG-PS, C–P 
class, neoplastic thrombosis, metastases, nodule size, pre-
sorafenib treatment and reason for sorafenib discontinua-
tion; Model 3 included MC therapy, ECOG-PS, neoplastic 
thrombosis, metastases, nodule size, ascites, pre-sorafenib 
treatment and reason for sorafenib discontinuation 
(Table 3). These models showed that MC therapy, pre-
sorafenib treatment of HCC, neoplastic thrombosis and 
liver decompensation during sorafenib administration were 
independently associated with PSS. In every model, MC 
therapy significantly reduced the mortality risk (reduction 
rate ranging from 34 to 40%) compared with BSC.
Finally, a sensitivity analysis was performed to test 
MC effect according to the causes of sorafenib discon-
tinuation. Interestingly, the greatest PSS benefit of MC 
with respect to BSC occurred in patients intolerant to 
sorafenib (p < 0.001), although a significant benefit was 
also detectable in those who experienced tumor progres-
sion (p = 0.005) (Fig. 3).
Fig. 2  Overall survival of patients from the date of sorafenib discontinuation to death before (a) and after (c) propensity score matching and sur-
vival of patients from the start date of sorafenib therapy to death before (b) and after (d) propensity score matching
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Safety
Table 4 reports the AEs observed during MC therapy. 
Overall, 84 patients (71.8%) experienced at least one (any 
grade) AE. Main drug-related AEs were fatigue (40.2%), 
thrombocytopenia (12.8%) hand–foot skin reaction 
(10.3%) followed by diarrhea, rush and nausea/vomiting 
(7.7% respectively). Most of them were mild, and none 
directly caused death or drug discontinuation. In seven 
(6.0%) patients, AEs required a dose adjustment.
Discussion
Several trials testing the efficacy of second-line systemic 
therapies for patients with advanced HCC have failed (Llovet 
et al. 2013; Finn et al. 2012; Zhu et al. 2014, 2015; Bruix 
et al. 2017). The failure likely depended, for some agents, 
on an inadequate selection of patients owing to the lack of 
biomarkers able to predict the response to therapy (diluting 
bias) and, for other agents, on their toxicity in a “fragile” 
Table 3  Univariate and multivariate cox analysis of factors associated with mortality
Significant values are in bold
HCV hepatitis C virus; ECOG-PS eastern cooperative oncology group-performance status; AFP alpha-fetoprotein; BCLC Barcelona Clinic Liver 
Cancer; INR International Normalized Ratio; HR hazard ratio; CI confidence interval
Predictors Univariate Multivariate
Model 1 Model 2 Model 3
HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI) p
Age, years (continue) 0.99 (0.98–1.00) 0.209
Gender (male vs. female) 1.19 (0.86–1.65) 0.293
Etiology (HCV vs other) 0.97 (0.73–1.28) 0.816
Capecitabine (yes/no) 0.57 (0.43–0.74) < 0.001 0.66 (0.50–0.89) 0.006 0.60 (0.41–0.87) 0.007 0.63 (0.45–0.88) 0.007
ECOG PS
 0 (reference category) 1 1 1
 1 1.32 (0.99–1.75) 0.060 1.51 (1.07–2.13) 0.018 1.36 (0.99–1.86) 0.061
 2 2.06 (1.18–3.60) 0.011 1.82 (0.94–3.52) 0.074 1.63 (0.83–3.20) 0.160
Child–Pugh class
 A (reference category) 1 1 1
 B 1.40 (1.01–1.93) 0.044 1.27 (0.90–1.78) 0.175 1.24 (0.83–1.85) 0.300
Neoplastic thrombosis (yes/no) 1.52 (1.12–2.08) 0.008 1.55 (1.09–2.20) 0.015 1.81 (1.28–2.56) 0.001
Metastases (yes/no) 1.38 (1.02–1.86) 0.037 1.14 (0.78–1.66) 0.488 1.37 (0.96–1.97) 0.082
Max. nodule size, mm (con-
tinue)
1.01 (1.00–1.01) 0.004 1.00 (1.00–1.01) 0.537 1.00 (1.00–1.01) 0.358
Pre-sorafenib treatment (yes/
no)
0.62 (0.46–0.84) 0.002 0.70 (0.51–0.97) 0.031 0.65 (0.45–0.92) 0.017 0.71 (0.50–1.00) 0.052
Sorafenib treatment duration, 
days (continue)
1.00 (0.98–1.02) 0.621
Reason for sorafenib discontinuation
 Adverse event (reference 
category)
1 1 1
 Tumor progression 1.30 (0.96–1.76) 0.093 1.26 (0.93–1.72) 0.135 1.54 (1.05–2.26) 0.027 1.22 (0.86–1.73) 0.270
 Liver decompensation 3.41 (1.36–8.54) 0.009 2.41 (0.92–6.32) 0.074 11.53 (3.76–35.35) < 0.001 9.43 (2.68–33.17) < 0.001
Ascites (yes/no) 1.42 (1.06–1.89) 0.018 1.19 (0.86–1.65) 0.294
BCLC (C vs B) 2.18 (1.25–3.82) 0.006 1.55 (0.86–2.79) 0.143
Bilirubin, mg/dL (continue) 1.16 (0.93–1.44) 0.204
Albumin, g/dL (continue) 0.83 (0.62–1.10) 0.184
INR, (continue) 0.93 (0.49–1.78) 0.834
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setting, such as liver cirrhosis, which is the background of 
most HCCs. A low toxicity of (or a predictable good toler-
ance to) the agent would represent, therefore, a key factor 
for the success in this clinical setting. Moreover, the strin-
gent criteria for entering into RCTs could have selected long 
natural history cases in placebo arms, owing to a selection 
bias of less-aggressive tumors (Llovet et al. 2015).
More recently, an  RCT has proven that regorafenib, a 
potent multikinase inhibitor, increases survival compared 
with placebo (HR 0.46; 95% CI 0.37–0.56) in patients who 
stopped sorafenib (Bruix et al. 2017). However, due to the 
expected overlap toxicity between the two drugs, this trial 
only included patients who had tumor progression but were 
tolerant to sorafenib, to curb the risk of regorafenib dis-
continuation for AEs. Therefore, this advancement in the 
management of advanced HCC does not represent a suitable 
option for the 28–40% of patients forced to stop sorafenib 
owing to its toxicity (Llovet et al. 2008; Iavarone et el. 
2011). Moreover, a press release has announced that in phase 
3 Celestial RCT cabozantinib has been proven to be an effec-
tive second-line treatment in patients with advanced HCC, 




Previous cohort studies, addressing the role of conven-
tional therapy with capecitabine (alone or in combination 
regimens), as first- or second-line systemic therapy for 
advanced HCC, have demonstrated a certain anti-tumor 
efficacy and low toxicity (Patt et al. 2004; Lee et al. 2009; 
He et al. 2013). A phase 2 trial, randomly assigning patients 
to sorafenib or capecitabine, showed a longer overall and 
progression-free survival of sorafenib patients but an imbal-
ance of C–P class distribution and extrahepatic tumor spread 
between groups affect the reliability of results (Abdel-Rah-
man et al. 2013).
The adjuvant role of conventional capecitabine after cura-
tive HCC resection was evaluated in an RCT including 60 
patients (Xia et al. 2010). The treatment reduced the risk of 
Fig. 3  Overall survival of 
metronomic capecitabine and 
best supportive care patients 
according to causes of sorafenib 
discontinuation
Table 4  Adverse events of metronomic capecitabine categorized 
according to the National Cancer Institute, Common Terminology 
Criteria for Adverse Events classification, version 4 (Marinelli et al. 
2013)
Any grade Grade 1–2 Grade 3–4
Number (%) Number (%) Number (%)
Drug related
 Fatigue 47 (40.2) 43 (36.8) 4 (3.4)
 Diarrhea 9 (7.7) 8 (6.8) 1 (0.9)
 Hand–foot skin reaction 12 (10.3) 11 (9.4) 1 (0.9)
 Rash 9 (7.7) 7 (6.0) 2 (1.7)
 Nausea/vomiting 9 (7.7) 9 (7.7)
 Leucopenia 7 (6.0) 6 (5.1) 1 (0.9)
 Thrombocytopenia 15 (12.8) 14 (11.9) 1 (0.9)
 Anemia 4 (3.4) 4 (3.4)
 Cardio toxicity 2 (1.7) 2 (1.7)
Not certainly drug related
 Itch 7 (6.0) 6 (5.1) 1 (0.9)
 Insomnia 3 (2.6) 3 (2.6)
 Bleeding 3 (2.6) 2 (1.7) 1 (0.9)
 Hyperbilirubinemia 32 (27.4) 28 (24.0) 4 (3.4)
 Ascites 36 (30.8) 29 (24.8) 7 (6.0)
 Encephalopathy 5 (4.3) 5 (4.3)
 Anorexia 2 (1.7) 2 (1.7)
 Edema 3 (2.6) 3 (2.6)
 Gastritis 1 (0.9) 1 (0.9)
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late tumor recurrence as compared to the supportive care 
and, once more, showed a good tolerability.
One study challenged the effectiveness of MC against 
BSC, using historical controls (Brandi et al. 2013). In this 
investigation, 90 patients with advanced HCC treated with 
MC (59 naïve and 31 post-sorafenib cases) showed a median 
OS of 14.5 and 9.8 months, respectively. In naïve patients, 
MC compared favorably with untreated patients matched for 
demographic and oncologic features (median OS: 15.6 vs. 
8.0 months), providing the proof-of-concept of its efficacy 
as first-line treatment. In another study, the median survival 
of 26 sorafenib-experienced patients undergoing MC was 8.0 
months (Granito et al. 2015). Lastly, a recent study showed 
that survival of patients sequentially treated with sorafenib 
and MC was significantly better than that of patients shifted 
to BSC at the time of sorafenib discontinuation (median OS: 
12.0 vs. 9.0 months, respectively), with a 46% reduction 
of death risk in MC cases (Casadei Gardini et al. 2017). 
Another indication of MC efficacy is provided by the long-
lasting objective TR reported in three patients with an unre-
sectable HCC (Brandi et al. 2010; Marinelli et al. 2013). On 
the other hand, a brief report by Murer et al. reported a short 
survival (mean: 6.3 months) in 25 HCC patients undergoing 
MC as both first- and second-line chemotherapy, with no 
significant differences between the two groups (Murer et al. 
2016). This poorer survival compared with that of our and 
previous studies (Brandi et al. 2013; Granito et al. 2015) 
could depend on the worse liver function and performance 
status of Murer’s patients.
In our study, median PSS was twofold higher in MC 
than in BSC patients, leading to a reduction of the death 
risk of about 35–40%. This result, confirming the previous 
one observed in a smaller group of sorafenib-experienced 
patients (Brandi et al. 2013), was corroborated by those 
obtained after adjustment for confounders in three differ-
ent multivariate models, and in a nested case–control study.
Furthermore, in line with the result of a previous multi-
centric Italian study (Casadei Gardini et al. 2017), the supe-
riority of MC over BSC was confirmed once survival was 
calculated from the beginning of sorafenib chemotherapy. 
This indicates that the sequential use of sorafenib and MC 
improves prognosis of HCC patients compared with the shift 
to BSC after withdrawal of the first-line therapy. The reli-
ability of this assumption is strengthened by the fact that OS 
of our control group receiving only sorafenib (10.7 months 
for unselected cases, and 12.0 months for matched cases; 
Fig. 2b, d) is well comparable with the figures reported by 
both the SHARP trial (Llovet et al. 2008) and a large field-
practice study (Iavarone et al. 2011).
Our results, however, should also be scrutinized in the 
light of PSS of our BSC patients (5.0 months), which was 
similar (4.6 months) to that reported by a large field-practice 
study (Lee et al. 2015) but shorter than that observed in 
placebo arms of the second-line RCTs (ranging from 7.3 to 
8.2 months) (Llovet et al. 2013; Finn et al. 2012; Zhu et al. 
2014, 2015; Bruix et al. 2017). This discrepancy may rely on 
the already mentioned selection bias favoring the inclusion 
in RCTs of patients with well-preserved general conditions 
and less-aggressive tumors (Llovet et al. 2015). Pertinently, 
23% of our patients belonged to C–P class B (which was an 
exclusion criterion for RCTs), about one-third had ascites, 
36% showed vascular invasion, and 76.4% had a metastatic 
disease. The worse clinical profile may also justify the fairly 
lower PSS of our MC patients (9.5 months) compared with 
patients undergoing regorafenib (10.6 months) (Bruix et al. 
2017).
Since the cause of sorafenib discontinuation has been 
claimed to be an important determinant of PSS (Iavarone 
et al. 2011), we also tested the effect of MC therapy. The 
treatment demonstrates its superiority over BSC either in 
patients intolerant to sorafenib or in those who had expe-
rienced tumor progression, but the greatest benefit was 
observed in those who did not tolerate sorafenib (Fig. 3). 
Therefore, MC appears to be useful regardless of the rea-
son of sorafenib withdrawal, but particularly in the patient 
population in which regorafenib has not been tested due to 
an expected risk of overlap toxicity between the two drugs. 
The benefit due to MC was likely assisted by a lower tumor 
aggressiveness and a more favorable natural history of the 
tumor in patients who discontinued first-line treatment for 
AEs (Iavarone et al. 2011).
Another result that needs a comment is the favorable 
prognostic meaning of locoregional treatments performed 
before sorafenib therapy. This unexpected finding may be 
tentatively explained assuming a lower biological aggres-
siveness of the tumor, which allowed to manage patients 
with sequential treatment before reaching an advanced stage.
In all mentioned studies, MC was well tolerated since no 
drug-related death occurred, AEs were generally mild and 
easily managed with dose reduction or brief periods of drug 
discontinuation. A permanent interruption of the therapy 
was seldom required. Our study confirmed that MC is a safe 
treatment for cirrhotic patients belonging to C–P class A or 
B (up to a score ≤ 8). Most of the AEs we observed (such 
as ascites, hyperbilirubinemia, edema, itching) cannot be 
certainly attributed to the drug, as they can be more likely 
ascribed to the liver disease. Indeed, drug-related AEs were 
generally mild or moderate, easily manageable with dose 
adjustment and/or symptomatic therapy, and they were never 
responsible for permanent drug withdrawal or patient death.
Lastly, it cannot be disregarded that MC is an inexpensive 
treatment (in Italy its cost is about 100 €/month), represent-
ing an approach to advanced HCC easily affordable by most 
National Health Systems.
Our study has several limitations. The principal one 
relies on its retrospective nature that may have introduced 
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unintended biases and precluded a pre-defined regimented 
follow-up with regard to clinical monitoring of HCC. Nev-
ertheless, it captured “real-world” observational data on 
MC efficacy and, hence, the shortcomings of the study 
design should be weighed against the pioneering nature 
of this multicenter investigation that included university 
and community institutions.
Second, patient enrollment was affected by a “monolat-
erality bias”, since not all the participating centers offered 
patients the two therapeutic options we compared. This 
shortcoming may, in turn, have caused a selection bias, as 
the lack of a second-line option could have compelled both 
physicians and patients toward a “stubborn” use of sorafenib 
(i.e., despite a documented progression) with respect to cent-
ers where MC was used as a rescue treatment. Although the 
similar exposure time to sorafenib in MC and BSC patients 
stands against this hypothesis, a certain impact of the mon-
olaterality bias cannot be fully excluded since BSC patients 
had poorer clinical status and greater tumor burden than MC 
cases. Hence, we tried to override this limitation assessing 
the effect of MC therapy on the survival adjusted for many 
confounders and after patient matching with the propensity 
score. After matching, BSC still had a larger tumor size, but 
this residual unbalance does not seem to be critical, since 
such a variable was not an independent prognosticator.
In conclusion, this study provides a proof-of-concept of 
the efficacy of MC and confirms its safety and efficacy as 
second-line treatment for patients with HCC and liver cir-
rhosis (C–P score ≤ 8) who either did not tolerate sorafenib 
or progressed during this therapy. It also indicates that the 
best results of MC can be expected in the former group of 
patients, representing an oncologic population still await-
ing for an effective and safe second-line treatment.
These promising results require confirmation through 
adequately sized RCTs comparing MC vs. regorafenib (for 
those experiencing sorafenib failure) or cabozantinib to 
exactly define the role of this safe and inexpensive therapy 
in the management of advanced HCC.
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